Shawn McCormick - Nevro Corp Independent Director
| NVRO Stock | USD 5.77 0.01 0.17% |
Director
Mr. Shawn T McCormick, CPA, is Independent Director of the Company. Mr. McCormick served as Chief Financial Officer of Tornier N.V., a public medical device company, from September 2012 to October 2015 when Tornier merged with Wright Medical Group. From April 2011 to February 2012, Mr. McCormick was Chief Operating Officer of Lutonix, Inc., a medical device company acquired by C. R. Bard, Inc. in December 2011. From January 2009 to July 2010, Mr. McCormick served as Senior Vice President and Chief Financial Officer of ev3 Inc., a public endovascular device company acquired by Covidien plc in July 2010. From May 2008 to January 2009, Mr. McCormick served as Vice President, Corporationrationrate Development at Medtronic, Inc., a public medical device company, where he was responsible for leading Medtronics worldwide business development activities. From 2007 to 2008, Mr. McCormick served as Vice President, Corporationrationrate Technology and New Ventures of Medtronic. From 2002 to 2007, Mr. McCormick was Vice President, Finance for Medtronics Spinal, Biologics and Navigation business. Prior to that, Mr. McCormick held various other positions with Medtronic, including Corporationrationrate Development Director, Principal Corporationrationrate Development Associate, Manager, Financial Analysis, Senior Financial Analyst and Senior Auditor. Prior to joining Medtronic, he spent four years with the public accounting firm KPMG Peat Marwick. He was a director of Entellus Medical, Inc., a public medical device company, and served as the chairman of the audit committee and as a member of the nominating and corporate governance committee from November 2014 to February 2018 when Entellus was sold to Stryker. Mr. McCormick was a director of SurModics, Inc., a public medical device and in vitro diagnostic technologies company, since December 2015 and serves on the audit committee and corporate governance and nominating committee. since 2014.
| Age | 56 |
| Tenure | 11 years |
| Professional Marks | CPA |
| Address | 1800 Bridge Parkway, Redwood City, CA, United States, 94065 |
| Phone | 650 251 0005 |
| Web | https://nevro.com |
Latest Insider Transactions
McCormick earned his M.B.A. from the University of Minnesota’s Carlson School of Management and his B.S. in Accounting from Arizona State University.Shawn McCormick Latest Insider Activity
Tracking and analyzing the buying and selling activities of Shawn McCormick against Nevro Corp stock is an integral part of due diligence when investing in Nevro Corp. Shawn McCormick insider activity provides valuable insight into whether Nevro Corp is net buyers or sellers over its current business cycle. Note, Nevro Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nevro Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Shawn McCormick over six months ago Disposition of 7518 shares by Shawn McCormick of Inspire Medical at 0.94 subject to Rule 16b-3 | ||
Shawn McCormick over six months ago Acquisition by Shawn McCormick of 716 shares of Inspire Medical subject to Rule 16b-3 |
Nevro Corp Management Efficiency
The company has return on total asset (ROA) of (0.0995) % which means that it has lost $0.0995 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4329) %, meaning that it created substantial loss on money invested by shareholders. Nevro Corp's management efficiency ratios could be used to measure how well Nevro Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of March 2025, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.29. At this time, Nevro Corp's Non Current Assets Total are very stable compared to the past year. As of the 23rd of March 2025, Intangible Assets is likely to grow to about 25.6 M, while Total Assets are likely to drop about 473.1 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Brian Concannon | CONMED | 62 | |
| Alvin Jeffers | Integer Holdings Corp | 47 | |
| Kristina Wright | Paragon 28 | 47 | |
| John Workman | CONMED | 69 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Fred Hite | Orthopediatrics Corp | 57 | |
| Mark Foley | Glaukos Corp | 55 | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
| Kristen CFA | Integer Holdings Corp | N/A | |
| Martha Aronson | CONMED | 53 | |
| David Hoffmeister | Glaukos Corp | 66 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| Aimee Weisner | Glaukos Corp | 51 | |
| Gilbert Kliman | Glaukos Corp | 61 | |
| Charles Farkas | CONMED | 68 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
| Joel Suiter | SurModics | N/A | |
| William Summers | Integer Holdings Corp | 70 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| Marc Stapley | Glaukos Corp | 50 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0995 |
Nevro Corp Leadership Team
Elected by the shareholders, the Nevro Corp's board of directors comprises two types of representatives: Nevro Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nevro. The board's role is to monitor Nevro Corp's management team and ensure that shareholders' interests are well served. Nevro Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nevro Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Dewey, Vice President - Investor Relations and Corporate Communications | ||
| Elizabeth Weatherman, Independent Director | ||
| Brad Vale, Independent Director | ||
| Donald Middlebrook, Vice President - Clinical, Regulatory and Quality | ||
| Christopher Christoforou, Vice President - Research and Development | ||
| Kevin OBoyle, Independent Director | ||
| Meredith Vornholt, Vice Marketing | ||
| Kashif JD, Senior Officer | ||
| Peter Socarras, General VP | ||
| Shawn McCormick, Independent Director | ||
| David Caraway, Chief Medical Officer | ||
| Christofer Christoforou, Senior Operations | ||
| DKeith Grossman, Chairman of the Board, President, Chief Executive Officer | ||
| Patrick Schmitz, Vice President - Operations | ||
| Richard Carter, Chief Officer | ||
| Sridhar Kosaraju, Director | ||
| Frank Fischer, Independent Director | ||
| Michael DeMane, Lead Independent Director | ||
| Kevin Thornal, CEO President | ||
| Roderick MacLeod, Chief Financial Officer | ||
| Greg Siller, Senior Officer | ||
| Shana MBA, Senior Officer | ||
| Michael Carter, Vice President - Global Sales | ||
| D Grossman, Chairman of the Board, President, Chief Executive Officer | ||
| Susan Siegel, Independent Director | ||
| Karen Prange, Independent Director | ||
| Angeline McCabe, Vice Communications | ||
| Kashif Rashid, Chief Compliance Officer, General Counsel, Corporate Secretary | ||
| Geeta Kaveti, VP Officer | ||
| Niamh Pellegrini, Chief Commercial Officer | ||
| Lori Ciano, Chief Human Resource Officer | ||
| David MD, Senior Officer | ||
| Jon Shear, Senior Development |
Nevro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nevro Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0995 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | 180.04 M | ||||
| Shares Outstanding | 38.37 M | ||||
| Shares Owned By Insiders | 2.87 % | ||||
| Shares Owned By Institutions | 97.13 % | ||||
| Number Of Shares Shorted | 1.82 M | ||||
| Price To Earning | (63.38) X |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nevro Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Nevro Stock, please use our How to Invest in Nevro Corp guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nevro Corp. If investors know Nevro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nevro Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.06) | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets | Return On Equity |
The market value of Nevro Corp is measured differently than its book value, which is the value of Nevro that is recorded on the company's balance sheet. Investors also form their own opinion of Nevro Corp's value that differs from its market value or its book value, called intrinsic value, which is Nevro Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nevro Corp's market value can be influenced by many factors that don't directly affect Nevro Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nevro Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nevro Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nevro Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.